AU2012261741B2 - Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine - Google Patents

Abstract

C:\NRPortb\CIW XS4805418_1.DOC-11l12/2012 Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of M. hyopneumoniae thereby reducing the severity of and/or preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent M. hyopneumoniae and compositions, comprising Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2) in further combination with an adjuvanted live avirulent M. hyopneumoniae.

Description

C:WRPonbDCC\RXS48054t3_1D0C- 1/12/2012 MYCOPLASMA HYOPNEUMONIAE AVIRULENT-ADJUVANTED LIVE VACCINE This is a divisional of Australian Patent Application No. 2008324780, the entire contents of which are incorporated herein by reference. FIELD OF THE INVENTION The present disclosure relates generally to the fields of Immunology and veterinary medicine. More specifically, the present disclosure provides adjuvanted live avirulent M. hyopneumoniae compositions based on a J strain of M. hyopneumoniae, including immunogenic or vaccine compositions, which aid in reducing the severity of and/or In preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are adjuvanted live avirulent M. hyopneumoniae compositions, including immunogenic or vaccine compositions, further comprising Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2). One or two-dose administration to an animal of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity, including cell-mediated immunity and/or humoral immunity, from infection with a virulent strain of M. hyopneumoniae. BACKGROUND OF THE INVENTION Mycoplasma hyopneumoniae (also referred to as M. hyopneumoniae) is the etiologic agent of swine mycoplasmal pneumonia. The disease causes a chronic cough, dull hair coat, retarded growth and unthrifty appearance lasting several weeks. Characteristic lesions of purple to gray areas of consolidation, particularly in ventral apical and cardiac lobes are observed in infected animals. Although the disease causes little mortality, affected swine are often prone to secondary infections by opportunistic pathogens, resulting In death or stress. (R. F. Ross, Mycoplasmal diseases, pp. 436-444, in A. D. Laman, et al, (eds.) Diseases of Swine, Iowa State University Press, 1986). The disease is believed to be one of the most important causes of disease-associated loss in swine (Whittlestone, pp. 133-176, in Tully and Whitcomb (eds.), The Mycoplasma Vol 2: Human and Animal Mycoplasmas, New York, Academic Press, (1979)). The disease generally results in inefficient weight gainers, and in stunted and sickly animals. Also, affected swine are often prone to secondary infection by opportunistic organisms (Burch, Pig America pp. 26-27, December, 1982). The economic impact of the disease is significant. Economic losses alone have been estimated at between 200 to 250 million dollars annually. Mycoplasma hyopneumoniae Is a slow growing, fastidious bacterium that lacks a cell wall. It is frequently difficult to isolate from the respiratory tract due to Mycoplasma hyorhinis, a common secondary agent also located in the respiratory tract. The disease is spread by aerosol, produced by coughing, and by direct contact from an affected or convalescent carrier swine. Mingling of infected animals and uninfected animals results in early and frequent reinfection. Infection frequently starts with infection of piglets by carrier sows at farrowing. Due to herd management techniques, infection may not become evident until later in 5 life. Additional infection usually is observed after weaning when pigs are pooled. Overt disease is normally observed in pigs at six weeks of age or older. Growth rates and feed conversion rates are markedly reduced in affected animals. Existing treatments using antibiotics are expensive and require prolonged use. Animal reinfection remains a problem. Thus, vaccines are presently the most effective method for avoiding infections and their 10 consequences. There have been numerous attempts to provide a vaccine for protecting swine against Mycoplasma hyopneumoniae infection. Several investigators have disclosed vaccines comprising recombinantly produced surface antigens of Mycoplasma hyopneumoniae, Schaller et al., U.S. Patent No. 4,894,332, issued Jan. 16, 1990; European Patent Publication No. 283,840, published Sep. 28, 1988. PCT Publication No. WO 15 86/00019, published Jan. 3, 1986, discloses a Mycoplasma hyopneumoniae vaccine comprising exclusively Mycoplasma hyopneumoniae plasma membranes, free of other cell components. Etheridge et a/., Res. Vet. Sci. 33:188 (1982), found incomplete protection against lung colonization by Mycoplasma hyopneumoniae when a live vaccine was given intravenously, subcutaneously, or intraperitoneally. Kristensen et aL, Am. J. Vet. Res. 20 42:784 (1981), found no protection of swine against mycoplasmal pneumonia after injection with heat-inactivated Mycoplasma hyopneumoniae. Ross et aL, Am. J. Vet. Res. 45:1899 (1984), found that use of Mycoplasma hyopneumoniae extracts prepared by a freeze-thaw procedure to immunize swine, provided only variable protection, and in some instances, enhanced lesson development was noted in immunized swine. These investigators also 25 studied a whole-cell vaccine prepared by formalin inactivation. Formalin inactivation significantly hindered the protective immunogenicity of Mycoplasma hyopneumoniae, and this vaccine was not effective. Yoshioka et al., U.S. Patent No. 3,917,819 (issued Nov. 4, 1975) discloses several killed Mycoplasma vaccines comprising Mycoplasma inactivated with formalln, Including an inactivated vaccine for Mycoplasma hyopneumoniae. Chung 30 Nan European Patent Publication 571,648 disclosed an M. hyopneumoniae vaccine based on the highly proliferative and antigenic strain PRIT-5. Vaccines based on inactivated virulent Mycoplasma hyopneumoniae strains are commercially available. Fort Dodge Animal Health (FDAH) markets Mycoplasma hyopneumoniae bacterin under the name Suvaxyn@ and Respifend@ Mycoplasma 35 hyopneumoniae for use as a vaccine to protect healthy swine against clinical signs caused -2by Mycoplasma hyopneumoniae. This bacterin vaccine is recommended as a two-dose vaccine for pigs at least one-week old, with the second dose two to three weeks after the first vaccination. The M. hyopneurnoniae J strain is a non-pathogenic strain with reduced capacity to 5 adhere to porcine cilia and, therefore, to cause disease. Castro et al., Veterinary Microbiology 116:258-269 (2006) and Vasconcelos et aL, J. Bacteriol. 187(16):5568-5577 (2005) (describing the complete genome sequence of M. hyopneumoniae J strain (ATCC 25934)). Genomic comparisons between pathogenic and nonpathogenic strains (J strain) have revealed variations in surface proteins, including cilium adhesin, that are believed to be 10 determinative of relative pathogenic properties between M. hyopneumoniae strains. Vasconcelos et al. (2006) and Djordjevic et a/., Infection and Immunity 72(5):2791-2802 (2004). M. hyopneumonia expresses, on its cell surface, membranous lipoproteins, particularly the P46, P65, and P97 proteins, which carry species-specific antigenic determinants. 15 Recently, Bouh et al. described monoclonal antibodies to P46 and P65 of live avirulent M. hyopneurnoniae reference J strain ATCC 25934. Clin. Diag. Lab. Immunology 10(3):459 468 (2003). Blank and Stemke described a physical and genetic map of M. hyopneumoniae strain J genome, Can. J. Microbiol. 46:832-840 (2000), and Wilton et al. described the screening of expression libraries generated from the non-pathogenic M. hyopneumoniae J 20 strain and the screening of those libraries with porcine hyperimmune antiserum against M. hyopneumoniae. There is a need for compositions, including immunogenic or vaccine compositions, made from live adjuvanted avirulent Mycoplasma hyopneumoniae, which compositions provide efficacy against virulent strains of M. hyopneurnoniae. The citation of any reference 25 herein should not be deemed as an admission that such reference is available as prior art to the instant invention. SUMMARY OF THE INVENTION The present disclosure provides compositions, including immunogenic compositions or 30 vaccine compositions, comprising an immunologically effective amount of a live avirulent Mycoplasma hyopneumoniae and a biologically acceptable adjuvant. Compositions disclosed herein elicit an immune response against Mycop/asma hyopneumoniae, thereby preventing and/or minimizing the severity of disease caused by this organism or ameliorating at least one symptom associated with the disease. -3- H:\amt\Intrwovn\NRPortbl\DCC\AMT\9243239_I.docx-5/01/2016 Accordingly, in one aspect, the invention provides a composition for eliciting an anti-Mycoplasma hyopneumoniae immune response in an animal, said composition comprising an immunologically effective amount of a live avirulent strain of Mycoplasma hyopneumoniae and a biologically acceptable adjuvant. 5 In one embodiment, the composition comprises a live avirulent strain of Mycoplasma hyopneumoniae whose genome comprises a nucleic acid sequence having at least about 90% homology to the nucleic acid sequence of a reference J strain. In one embodiment, the composition comprises a live avirulent strain of Mycoplasma hyopneumoniae whose genome comprises a nucleic acid sequence having at 10 least about 95% homology to the nucleic acid sequence of a reference J strain. In one embodiment, the composition comprises a live avirulent strain of Mycoplasma hyopneumoniae whose genome comprises a nucleic acid sequence having at least about 99% homology to the nucleic acid sequence of a reference J strain. In one embodiment, the composition comprises a live avirulent strain of 15 Mycoplasma hyopneumoniae that has at least about 70% polymorphic identity to a reference J strain. In one embodiment, the composition comprises a live avirulent strain of Mycoplasma hyopneumoniae that has at least about 85% polymorphic identity to a reference J strain. 20 In one embodiment, the composition comprises a live avirulent strain of Mycoplasma hyopneumoniae that has at least about 95% polymorphic identity to a reference J strain. In one embodiment, the percent homology of the live avirulent strain of Mycoplasma hyopneumoniae used in the compositions described herein are determined by 25 comparison to an avirulent reference J strain having ATCC accession number 25934 (GenBank Accession Number AE017243; SEQ ID NO:1) or 27715. In other certain embodiments, the reference strain may be a strain that is a virulent strain, for example, those having ATCC accession numbers 25617 or 25095. In one embodiment, the percent polymorphic identity of the live avirulent strain of 30 Mycoplasma hyopneumoniae used in the compositions described herein are determined by comparison to an avirulent reference J strain having ATCC accession number 25934 or -4- H:\am\Introvn\NRPortbl\DCC\AMT\9243239_I.docx-5/01/2016 27715. In other certain embodiments, the reference strain may be a strain that is a virulent strain, for example, those having ATCC accession numbers 25617 or 25095. In one embodiment, the live avirulent strain of Mycoplasma hyopneumoniae used in the compositions described herein is a J strain designated as ATCC accession number 5 25934 or 27715. In one embodiment, the live avirulent strain of Mycoplasma hyopneumoniae used in the compositions described herein is a J strain designated as ATCC accession number 27715. -4A- In one embodiment, the immune response elicited by a live-avirulent strain of Mycoplasma hyopneumoniae protects an animal against infection with, or reduces the severity of at least one symptom associated with an infection by a virulent strain of Mycoplasma hyopneumoniae. 5 In one embodiment, one-dose administration to an animal of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal from Mycopfasma infection. In one embodiment, two-dose administration to an animal of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity 10 to the animal from Mycoplasma infection. Adjuvanted live avirulent Mycoplasma hyopneumoniae vaccine compositions disclosed herein may be suitably employed for use in swine against infection and disease caused by Mycopfasma hyopneumoniae and will find utility in managing and/or preventing the spread of infection and disease caused by Mycoplasma hyopneumoniae in swine populations. 15 Thus, immunogenic compositions and vaccine compositions of the present disclosure employ one or more live avirulent Mycoplasma hyopneumoniae in combination with one or more adjuvant such as a biologically acceptable adjuvant. The biologically acceptable adjuvant may, optionally, be one or more adjuvant(s) selected from the group consisting of SP-Oil, SL-CD, an acrylic acid polymer (such as Carbopol@, Noveon, Inc., Cleveland, OH), 20 and a mixture of a metalizable oil such as one or more unsaturated terpene hydrocarbon(s), for example squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic@ (BASF, Florham Park, New Jersey). The concentration of adjuvant employed in the compositions described herein will depend upon the nature of the adjuvant. Adjuvants are typically present in the compositions 25 described herein at a final concentration of about 1-50% (v/v) and more typically at a final concentration of about 10%, 15%, 20%, 25%, or 30% (v/v). In compositions comprising SP oil, the adjuvant is typically present at between about 1% and about 25% (v/v), more typically between about 5% and about 15% (v/v) such as, for example, at about 10% (v/v). In compositions comprising an acrylic acid polymer and a mixture of a metabolizable oil that 30 comprises one or more terpene hydrocarbon(s) and a polyoxyethylene-polypropylene block copolymer, the ratio of acrylic acid polymer to metabolizable oil/polyoxyelhylene polypropylene block copolymer mixture is typically in a ratio of between about 1:25 and about 1:50 and typically at a final concentration of between about 1% and about 25% (v/v). In one embodiment, the biologically acceptable adjuvant comprises SP-Oil. In one 35 embodiment, the SP-Oil is present at a concentration of between about 1% and about 25% -5v/v. In one embodiment, the SP-OiI is present at a concentration of between about 5% and about 15% v/v. In one embodiment, the SP-Oil is present at a concentration of about 10% v/v. Within certain embodiments, compositions disclosed herein may employ, in further 5 combination, one or more other live bacteria, bacterin, toxoid, and/or viral antigen. Thus, within certain aspects of these embodiments, the adjuvanted live avirulent M. hyopneumoniae composition may comprise an immunologically effective amount of live avirulent Mycoplasma hyopneumoniae and one or more biologically acceptable adjuvant(s) in further combination with (a) one or more live bacteria; (b) one or more bacterin; (c) one or 10 more purified toxoid from one or more pathogens such as, for example, Haemophilus parasuis, Pasteurel/a multocida, Streptococcus suis, Actinobaclilus pleuropneumoniae, Bordetella bronchiseptica, Saimonella choleraesuis, Erysipelothrix rhusiopathiae and leptospira bacteria; and/or (d) one or more viral antigen wherein the virus is selected from the group consisting of swine influenza virus (SIV), porcine reproductive and respiratory 15 syndrome virus (PRRSV), raccoon poxvirus expressing PRRS and/or other antigens, TGEV expressing PRRS and/or other antigens, and porcine circovirus (PCV). Within certain aspects of these embodiments, exemplified herein are compositions, including immunogenic compositions or vaccine compositions, which employ, in further combination, Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2). Within these or 20 alternative embodiments, compositions, including immunogenic or vaccine compositions, may additionally or optionally include a preservative and stabilizer such as, for example, SGGK, thimerosol and/or EDTA. The concentration of such other live bacteria, bacterin, toxoid, and/or viral antigen employed in the compositions described herein will depend upon the nature of the live 25 bacteria, bacterin, toxoid, and/or viral antigen and are typically present in the compositions described herein. For such compositions wherein the other antigen is bacterial, the bacteria are typically present at a final concentration of between about 0.5 x 106 to 0.5 x 1010 per milliliter. Alternatively, the bacteria are present at a final concentration of between about 0.5 x 106 to 0.5 x I0 per milliliter or at a final concentration of between about 0.5 x 10 7 to 0.5 x 30 10" per milliliter. A second aspect of the invention provides methods for generating an immune response to Mycoplasma hyopneumoniae, or for protecting an animal against disease caused by Mycoplasma hyopneumoniae and/or for preventing or ameliorating an outbreak of such disease among animal populations by administering an adjuvanted live avirulent 35 Mycop/asma hyopneumoniae composition as described herein. In a related aspect, the - 6present disclosure also provides methods for enhancing an immune response to Mycoplasma hyopneumoniae. Such methods comprise the steps of administering to an animal, such as swine, in one or two doses, a composition comprising one or more adjuvanted live avirulent Mycoplasma hyopneumoniae strain. 5 In one embodiment the methods of the present invention use a live avirulent strain of Mycoplasma hyopneumoniae whose genome comprises a nucleic acid sequence having about 90% homology to the nuclelc acid sequence of a reference J strain. In one embodiment the methods of the present invention use a live avirulent strain of Mycoplasma hyopneumoniae whose genome comprises a nucleic acid sequence having 10 about 95% homology to the nucleic acid sequence of a reference J strain. In one embodiment the methods of the present invention use a live avirulent strain of Mycoplasma hyopneumoniae whose genome comprises a nucleic acid sequence having about 99% homology to the nucleic acid sequence of a reference J strain. In one embodiment the methods of the present invention use a live avirulent strain of 15 Mycoplasma hyopneumoniae that has at least about 70% polymorphic identity to a reference J strain. In one embodiment the methods of the present invention use a live avirulent strain of Mycopfasma hyopneumoniae that has at least about 85% polymorphic identity to a reference J strain. 20 In one embodiment, the methods of the present invention use a live avirulent strain of Mycoplasma hyopneumoniae that has at least about 95% polymorphic identity to a reference J strain. In one embodiment, the live avirulent strain of Mycoplasma hyopneunoniae used in the methods of the invention, as described herein, is a J strain designated as ATCC accession 25 number 25934 or 27715. In one embodiment, the live avirulent strain of Mycoplasma hyopneumoniae used in the methods of the invention, as described herein, is a J strain desIgnated as ATCC accession number 27715. In one embodiment, the Invention provides a method for enhancing an immune 30 response to Mycoplasma hyopneumoniae, the method comprising the steps of: a) at a first time, administering a first immunogenic composition comprising an immunologically effective amount of a live avirulent Mycopfasma hyopneumoniae strain adjuvanted with a biologically acceptable adjuvant material to an animal; -7b) at a second time, administering a second immunogenic composition comprising an immunologically effective amount of a live avirulent Mycoplasma hyopneumoniae adjuvanted with a biologically acceptable adjuvant material to an animal. In certain embodiments, depending upon the precise application contemplated, 5 compositions may be administered parenterally, such as through intramuscular, subcutaneous, or intraperitoneal injection, or by topical application of a cream. Alternatively, compositions may be administered through aerosol, intranasal, or oral routes, such as by intranasal spray or oral administration by hand delivery or mass application. A third aspect of the invention provides use of the Mycoplasma hyopneumoniae 10 strains described herein and compositions comprising these strains for preparation of a medicament for treating an animal suffering from an infection with Mycoplasma hyopneumoniae or suffering from at least one symptom associated with an infection with Mycoplasma hyopneumoniae. These and other embodiments, features and advantages of the invention will become 15 apparent from the detailed description and the appended claims set forth herein below. All patents, patent applications, and other literature cited herein are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure will prevail. DETAILED DESCRIPTION OF THE INVENTION 20 Before the present methods and treatment methodology are described, it is to be understood that this invention is not limited to particular methods, and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. 25 As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, references to "the method" includes one or more methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth. 30 Accordingly, in the present application, there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); 35 DNA Cloning: A Practical Approach, Volumes I and II (D.N. Glover ed. 1985); -8- Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. (1985)); Transcription And Translation (B.D. Hames & S.J. Higgins, eds. (1984)); Animal Cell Culture (R.I. Freshney, ed. (1986)); Immobilized Cells And Enzymes (IRL Press, (1986)); B. Perbal, A Practical Guide To Molecular Cloning (1984); F.M. Ausubel 5 et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994). Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated by reference in their entirety. 10 DEFINITIONS The terms used herein have the meanings recognized and known to those of skill in the art, however, for convenience and completeness, particular terms and their meanings are set forth below. 15 The term "about" or "approximately" means within a statistically meaningful range of a value. Such a range can be within an order of magnitude, typically within 50%, more typically within 20%, more typically still within 10%, and even more typically within 5% of a given value or range. The allowable variation encompassed by the term "about" or "approximately" depends on the particular system under study, and can be readily 20 appreciated by one of ordinary skill in the art. "Adjuvant" means a composition comprised of one or more substances that enhances the antigenicity of live avirulent Mycoplasma hyopneumoniae in a composition, typically a vaccine composition. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune 25 response (Hood, et al., Immunology, Second Ed, Menlo Park, CA: Benjamin/Cummings, 1984. p. 384). Often, a primary vaccination with an antigen alone, in the absence of an adjuvant, will fail to elicit a humoral or cellular immune response. Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, 30 polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, and potentially useful human adjuvants such as N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphos phoryloxy)-ethylamine, BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Preferably, the adjuvant is 35 biologically acceptable. - 9- Adjuvants employed in the compositions described herein are typically "biologically acceptable adjuvants" and, thus, may be used in combination with live avirulent Mycoplasma hyopneumoniae such that the resulting compositions may be administered in vivo without concomitant toxicity to an animal. Exemplified herein are compositions including live 5 avirulent Mycoplasma hyopneumoniae in combination with one or more biologically acceptable adjuvant selected from the group consisting of SP-Oil, SL-CD, Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbon(s), for example squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic@. 10 A live avirulent Mycoplasma hyopneumoniae strain or molecule therefrom is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. Typically, an antigenic molecule is a polypeptide, or variant thereof, which contains an ".epitope" of at least about five and typically at least about 10 amino acids. An antigenic 15 portion of a polypeptide, also called herein the "epitope," can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier polypeptide for immunization. A molecule that is antigenic need not be itself immunogenic, i.e., capable of eliciting an immune response without a carrier. 20 The term "at least" means not less than. As used herein, a "bacterin" is a bacterium harvest that has been inactivated and that, in combination with certain adjuvants, can elicit protective immunity to protect against disease or infection when administered to animals. Acrylic acid polymers are typically carbomers. Carbomers are commercially available 25 under the trade name "Carbopol" and are described, for example, in U.S. Patent Nos. 2,909,462 and 3,790,665, each of which is incorporated herein by reference. The term "carrier" refers to a diluent, adjuvant, excipient, stabilizer, preservative, and/or vehicle with which a compound or composition is administered. Such carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or 30 synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions, for example, phosphale-buffered saline, Ringer's solutions and aqueous dextrose and glycerol solutions are frequently employed as carriers, particularly for injectable solutions. The carrier or diluent must be non-toxic and must not affect the biological activity of the antigen/immunogen. Other additional auxiliary subatances, 35 such as wetting or emulsifying agents, surfactants, pH buffering sbatances and the like may -10also be used in the compositions of the invention. Preservatives may include, for example, thimerosol and/or EDTA. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, 1 8h Edition. A wide variety of carriers are well known in the art, and the selection of specific carriers is well within the level of those skilled 5 in the art. The term "colony forming unit" or "CFU" is a unit of measure used to indicate the number of organisms capable of replication in a given sample. This is based on the theory that a colony is derived from the replication of a pair/cluster or single cell of bacteria. The "immunologically effective amount" is the amount of live avirulent Mycoplasma 10 hyopneumoniae that will elicit an immune response against Mycoplasma hyopneumoniae. The "immunologically effective amount" will depend upon the species, breed, age, size, health status of the recipient animal and will be influenced by the previous exposure of the animal to one or more strain of Mycoplasma hyopneumoniae whether that one or more strain is a virulent strain or an avirulent strain of Mycoplasma hyopneumoniae. As used herein, an 15 immunologicallyy effective amount" of live avirulent Mycoplasma hyopneumoniae, when employed in combination with a suitable adjuvant, is that amount of Mycoplasma hyopneumoniae that is sufficient to enhance the immunogenicity of the live avirulent Mycoplasma hyopneumoniae and thus provides for protective immunity against challenge with a virulent Mycoplasma hyopneumoniae strain. In one embodiment, an immunologically 20 effective amount is a minimum of about I x 103 organisms. In one embodiment, an immunologically effective amount ranges from about 1 X 10 3 colony forming units/ml (CFU/ML) to about I X 10 CFU/ML. In one embodiment, an immunologically effective amount is about 5 X 10 7 CFU/ML. As used herein, the term "immunogenic" means that the live avirulent Mycoplasma 25 hyopneumoniae is capable of eliciting a humoral and/or cellular immune response. An immunogenic strain is also antigenic. An immunogenic composition is a composition that elicits a humoral and/or cellular immune response when administered to an animal. The term "immunogenic composition" relates to any pharmaceutical composition containing an antigen, eg. a microorganism, which composition can be used to elicit an 30 immune response in a mammal. The immune response can include a T cell response, a B cell response, or both a T cell and B cell response. The composition may serve to sensitize the mammal by the presentation of antigen in association with MHC molecules at the cell surface. In addition, antigen-specific T-lymphocytes or antibodies can be generated to allow for the future protection of an immunized host. An "immunogenic composition" may contain 35 a live, attenuated, or killed/inactivated vaccine comprising a whole microorganism or an - 11 immunogenic portion derived therefrom that induces either a cell-mediated (T cell) immune response or an antibody-mediated (B cell) immune response, or both, and may protect the animal from one or more symptoms associated with infection by the microorganism, or may protect the animal from death due to the infection with the microorganism. 5 As used herein, the term "isolated" means that the referenced material is removed from its native environment. Thus, an isolated biological material can be free of some or all cellular components, i.e., components of the cells in which the native material occurs naturally (e.g., cytoplasmic or membrane component). A material is isolated if it is present in a cell extract or supernatant. An isolated protein may be associated with other proteins or 10 nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane-associated protein. An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism. An isolated material may be, but need not be, purified. As used herein, the term "MHDCE" designates Mycoplasma hyopneumoniae DNA cell 15 equivalents and is defined as a unit of measure used to determine the approximate number of Mycoplasma hyopneumoniae organisms present in a given sample. The term "parenteral administration" as used herein means administration by some other means than through the gastrointestinal tract, particularly to the introduction of substances into an organism by intravenous, subcutaneous, intramuscular, or intramedullary 20 injection, but also to other non-oral and non-nasal routes of administration such as intraperitoneal injection or topical application. The term "polymorphic identity to a reference J strain" refers to similarity between the protein expression profile of one non-J strain Mycoplasma hyopneumoniae to a reference J strain of Mycoplasma hyopneumoniae. The polymorphic identity may be based on one or 25 more characteristics of one or more proteins, including, but not limited to, for example, the amount or size of one or more proteins of the Mycoplasma hyopneumoniae microorganism under investigation, to the sedimentation rate of one or more proteins, or to changes in the physical or biochemical characteristics of one or more proteins. The term may also include similarity between the nucleotide sequences that encode any one or more proteins of one 30 non-J strain of Mycoplasma hyopneumoniae and a reference J strain of Mycoplasma hyopneumoniae and includes any mutations in these sequences, including deletions or substitutions. The change in the nucleotide or amino acid sequence is one that allows for retention of the avirulent nature of the Mycoplasma hyopneumoniae organism. A wide variety of assays for observing perturbations in nucleotide and amino acid sequences are 35 well known in the art. For example, the size and structure of nucleic acid or amino acid - 12 sequences are observed by the Northern, Southern, Western, SDS-PAGE ELISA profiling, PCR and DNA sequencing protocols as known to those skilled in the art (see, e.g. Calus, D. et al Veterinary Microbiology, Vol. 120, Issues 3-4, March 10, 2007, pages 284-291; Scarman, AL, et al. Microbiology (1997), Vol. 143: 663-673). In addition, other methods for 5 observing perturbations in nucleotide and amino acid sequences such as single strand conformation polymorphism analysis are well known in the art (see, e.g., U.S. Pat. No, 5,382,510 issued 7 Sep. 1999, and U.S. Pat. No. 5,952,170 issued 17 Jan. 1995). The term "purified" as used herein refers to material that has been isolated under conditions that reduce or eliminate the presence of unrelated materials, i.e., contaminants, 10 including native materials from which the material is obtained. For example, a purified bacteria or protein is typically substantially free of host cell or culture components, including tissue culture or egg proteins, non-specific pathogens, and the like. As used herein, the term "substantially free" is used operationally, in the context of analytical testing of the material. Typically, purified material substantially free of contaminants is at least 50% pure; 15 more typically at least 90% pure, and more typically still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art. Methods for purification are well known in the art. The term "substantially pure" indicates the highest degree of purity which can be achieved using conventional purification techniques known in the art. 20 A "reference strain" refers to a strain of microorganism, for example, Mycoplasma hyopneumoniae, that is obtained from a reliable source and which may be used as a control strain for which comparisons with other unestablished or unkown cultures may be compared. In the present invention, the reference strains of Mycoplasma hyopneumoniae may be avirulent J strains that are obtained from the American Type Culture Collection (ATCC) and 25 are assigned ATCC accession numbers 25934 and 27715. In the present invention, these "reference strains" having ATCC accession numbers 25934 or 27715 have also been used to prepare the immunogenic compositions of the invention. In other certain embodiments of the present invention, the reference strains of Mycoplasma hyopneumoniae may be obtained from the American Type Culture Collection (ATCC) and are assigned ATCC accession 30 numbers 25617 and 25095. The term "SL-CD" refers to a sulpholipo-cyclodextrin that falls within the family of cyclodextrin adjuvants described in U.S. patent numbers 6,610,310 and 6,165,995. Typically, SL-CD is formulated in a mixture with a metabolizable oil such as one or more unsaturated terpene hydrocarbons, for example, squalane and preferably with a non-ionic 35 surfactant, such as polyoxyethylene sorbitan monooleate. - 13- The term "SP-Oil" refers to an adjuvant that is an oil emulsion comprising: 1% to 3% vol/vol of polyoxyethylene-polyoxypropylene block copolymer; 2% to 6% vol/vol of squalane; 0.1% to 0.5% vol/vol of polyoxyethylene sorbitan monooleate; and a buffered salt solution. 5 The terms "vaccine" or "vaccine composition", which are used interchangeably, refer to pharmaceutical compositions comprising at least one immunogenic composition that induces an immune response in an animal. A vaccine or vaccine composition may protect the animal from disease or possible death due to an infection, and may or may not include one or more additional components that enhance the immunological activity of the active 10 component. A vaccine or vaccine composition may additionally comprise further components typical to pharmaceutical compositions. A vaccine or vaccine composition may additionally comprise further components typical to vaccines or vaccine compositions, including, for example, an adjuvant or an immunomodulator. The immunogenically active component of a vaccine may comprise complete live organisms in either their original form, 15 or as attenuated organisms in a modified live vaccine, or organisms inactivated by appropriate methods in a killed or inactivated vaccine, or subunit vaccines comprising one or more immunogenic components of the virus, or genetically engineered, mutated or cloned vaccines prepared by methods known to those skilled in the art. A vaccine or vaccine composition may comprise one or simultaneously more than one of the elements described 20 above. As used herein, "virulent" refers to the ability of a Mycoplasma hyopneumoniae strain to cause disease associated with Mycoplasma hyopneumoniae infection. Virulence can be evaluated by observing disease progression in the animal. An example of a "virulent" strain of Mycoplasma hyopneumoniae is that exemplified by the challenge strain of Mycoplasma 25 hyopneumoniae, as described and used in the present invention. Other virulent strains of Mycoplasma hyopneumoniae are available from the American Type Culture Collection (ATCC), designated as Strain No. 25617 or 25095. The term "avirulent" refers to strains of Mycoplasma hyopneumoniae that are lacking in virulence. That is, avirulent strains, isolates, or constructs are non-pathogenic and are incapable of causing disease. As used herein the 30 term "avirulent" is used synonymously with the term "non-virulent." Exemplified herein are compositions employing the M. hyopneumoniae avirulent live culture strain J (FCX3-Line 1, which is available from the American Type Culture Collection (ATCC) as Strain No. 27715). Another "avirulent" strain that is also available from the ATCC is designated as Strain No. 25934. The J strain designated as ATCC accession number 27715 was cloned from the - 14parental J strain designated as ATCC accession number 25934, as described in the ATCC catalogue. GENERAL DESCRIPTION 5 The present disclosure is based upon the discovery that one or Iwo-dose regimens of a Mycoplasma hyopneumoniae composition, including an immunogenic composition or a vaccine composition, using one or more live avirulent Mycoplasma hyopneumoniae, such as, for example, strain J (FCX3-Line 1; ATCC Accession No. 27715) and one or more adjuvant, typically a biologically-acceptable adjuvant, are effective in protecting against and/or 10 preventing or ameliorating disease associated with virulent Mycoplasma hyopneumoniae infection. In one embodiment, other live avirulent strains of Mycoplasma hyopneumoniae, including, but not limited to, J strains, whose genome comprises a nucleic acid sequence having at least about 90% homology, or at least about 95% homology, or at least about 99% 15 homology, with a reference J strain, are contemplated for use in the compositions and methods of the present invention. In one embodiment, other live avirulent strains of Mycoplasma hyopneumoniae, including, but not limited to, J strains, which have at least about 70% polymorphic identity, or at least about 85% polymorphic identity, or at least about 95% polymorphic identity, to that of 20 a reference J strain, are contemplated for use in the compositions and methods of the present invention. The reference J strain may be selected from the Mycoplasma hyopneumoniae strains designated as ATCC accession number 25934 or 27715. In one embodiment, the live avirulent J strain used in the compositions and methods 25 of the present invention is a J strain designated as ATCC accession number 25934 or 27715. In one embodiment, the live avirulent J strain used in the compositions and methods of the present invention is a J strain designated as ATCC accession number 27715. It is also disclosed herein that compositions, including vaccine compositions, which 30 employ one or more live avirulent Mycoplasma hyopneumoniae strain in further combination with Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2) (See U.S. Patent Publication number 2003/0170270 and number 2004/0253270) are also effective in protecting against and/or preventing or ameliorating disease associated with virulent Mycoplasma hyopneumoniae infection and/or virulent Porcine Circovirus infection. -15- In certain embodiments, the compositions of the invention further comprise one or more live bacteria, bacterin and/or one or more purified toxoid selected from the group consisting of Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetela bronchiseptica, Salmonella choleraesuis, 5 Erysipelothix rhusiopathiae, and leptospira bacteria. In certain embodiments, the compositions of the invention further comprise one or more viral antigen selected from the group consisting of a swine influenza virus (SIV) antigen, a porcine reproductive and respiratory syndrome virus (PRRSV) antigen, raccoon poxvirus expressing PRRS or other antigens, TGEV expressing PRRS or other antigens, 10 and a porcine circovirus (PCV) antigen. Within certain embodiments, the present disclosure is described hereinafter with reference to protection against infection with a lung homogenate designated as LI-34 containing virulent Mycoplasma hyopneumoniae strain 11 (See J. Clin. Microbiol. 1999 Mar; 37(3):620-7. It is, however, contemplated that the compositions disclosed herein will be 15 effective in protecting against and/or preventing or ameliorating disease or at least one symptom associated with the disease that are associated with a wide range of virulent Mycoplasma hyopneumoniae infections. Numerous virulent Mycoplasma hyopneumoniae isolates are known in the art and are available from various sources including the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852. Examples of these 20 virulent strains include, but are not limited to, ATCC accession numbers 25095, 27714 and 25617. Compositions, in particular immunogenic compositions or vaccine compositions, of the present disclosure may be prepared from lyophilized or freshly harvested cultures of live avirulent Mycoplasma hyopneumoniae by one or more methodology that is readily available 25 in the art. Exemplified herein are compositions comprising the live avirulent M. hyopneumoniae strain J (FCX3-line 1) which is available as ATCC Number 27715 (a filtered and cloned 3 times isolate of ATCC Number 25934). Live avirulent Mycoplasma hyopneumoniae may be cultured by the methodology described in U.S. Patent Nos. 5,338,543 and 5,565,205, each of which is incorporated in its 30 entirety herein. More specifically, Mycoplasma hyopneumoniae may be propagated in culture medium such as PPLO (Pleuropneumonia-Ilke organism) complete medium (Difco; Becton Dickinson and Company, San Jose, California). Growth of the organism is monitored by standard techniques such as determining color changing units (CCU), and harvested when a sufficiently high titer has been achieved. The stocks may be further concentrated or 35 lyophilized by conventional methods before inclusion in the composition formulations. Other -16methods, such as those described in Thomas at al, Agri-Practice 7(5):26-30, may also be employed. The conditions under which an isolate of Mycoplasma hyopneumoniae is grown may vary depending upon the precise composition of the medium and the specific isolate being 5 grown. Mycoplasma hyopneumoniae isolates are typically grown from about 48 hours to about 144 hours, measured from the time of incubation to the time of harvest. Depending upon the precise composition to be formulated, Mycoplasma hyopneumoniae may be concentrated by, for example, ultracentrifugation or ultrafiltration. The concentrated Mycoplasma hyopneumoniae may be recovered by methodology known in 10 the art and may be mixed with a suitable physiologically acceptable carrier - typically an aqueous media such as, for example, saline, phosphate-buffered saline (PBS), minimal essential media (MEM), or MEM with HEPES buffer. It may then be further combined with an appropriate adjuvant to provide the desired concentration on a volume per volume basis (v/v). Compositions may further comprise one or more chelator, such as EDTA, typically at a 15 concentration of about 0.05% to about 0.20% (wiv). Alternatively, the Mycoplasma hyopneumoniae strain to be used in the immunogenic or vaccine compositions may be concentrated as described above, or lyophilized and resuspended in an appropriate adjuvant at the desired concentration on a weight per volume (w/v) basis. As indicated above, compositions, including immunogenic compositions or vaccine 20 compositions, of the present disclosure generally comprise a live avirulent strain of Mycoplasma hyopneumontae in combination with one or more adjuvant, typically a biologically acceptable adjuvant, For one-dose administration, compositions may contain an amount of live avirulent Mycoplasma pneunomoniae corresponding to about 1 x 108 to about 3 x 1011 MHDCE/ml. 25 Alternatively, compositions may contain an amount of live avirulent Mycoplasma pneunomoniae corresponding to about 1 x 10 9 to about 3 x 100 MHDCE/ml. Compositions are formulated such that each administration dose will be between about one (1) ml and about five (5) ml, or between about two (2) ml, per animal for administration intramuscularly, subcutaneously, or intraperitoneally and between about one (1) and about ten (10) ml, or 30 between about two (2) and about five (5) ml, for administration orally or intranasally. For two-dose administration, compositions typically contain an amount of live avirulent Mycoplasma pneunomoniae of about I x 108 to about 3 x 1011 MHDCE/ml, more typically about I x 10 9 to about 3 x 10 9 MHDCE/ml. In certain embodiments for two dose administration, compositions may contain an amount of live avirulent Mycoplasma 35 pneumoniae containing about 10 3 CFU/ML TO 10 1 CFU/ML. Compositions are formulated -17such that each administration dose will be between about one (1) ml and about five (5) ml, preferably about two (2) ml per animal for administration intramuscularly, subcutaneously, or intraperitoneally and between about one (1) and about ten (10) ml, typically between about two (2) and about five (5) ml for administration orally or intranasally. 5 The adjuvant mixture for use in the immunogenic compositions and vaccine compositions of the present disclosure enhances the immune response by stimulating cell mediated and/or local (secretory IgA) immune responses. The biologically acceptable adjuvant may, for example, be one or more adjuvant selected from the group consisting of SP-Oil, SL-CD, an acrylic acid polymer (such as Carbopol), and a mixture of a metabolizable 10 oil such as one or more unsaturated terpene hydrocarbon(s), for example squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic@. Adjuvants may be further selected from cytokines, such as IL-12 and IL-18; aluminum hydroxide; ethylene maleic acid copolymer; DEAE dextran; mycobacteria cell wall derived adjuvant; and the like. 15 The concentration of adjuvant employed in the compositions described herein will depend upon the nature of the adjuvant. Adjuvants are typically present in the compositions described herein at a final concentration of about 1-50% and more typically at a final concentration of about 10%, 15%, 20%, 25%, or 30%. The concentration of the antigen in the adjuvant may be prepared on a weight per volume basis (w/v) or on a volume per 20 volume (v/v) basis. For example, the antigen to be delivered in the compositions of the invention may be prepared in a lyophilized form, followed by reconstitution in the adjuvant directly to result in the specified concentrations on a weight per volume basis. Alternatively, the antigen may first be reconstituted in an appropriate diluent (for example, a buffer) to which is then added an adjuvant in a volume sufficient to result in the final desired 25 concentration of both antigen and adjuvant on a volume per volume basis, as described above. In certain embodiments, an adjuvant may be administered with the antigen/immunogen as a single composition, or can be administered before, concurrent with, or after administration of the antigen/immunogen. 30 The choice of the adjuvant depends on the stability of the antigen/immunogen containing the adjuvant, the route of administration, the dosing schedule, the efficacy of the adjuvant for the species being vaccinated and must also be one approved for use in animals or humans by the pertinent regulatory bodies. In compositions comprising SP-Oil, the adjuvant is typically present at between about 35 1% and about 25% (vlv), more typically between about 5% and about 15% (v/v) such as, for -18example, at about 10% (v/v); in compositions comprising an acrylic acid polymer and a mixture of a metabolizable oil that comprises one or more terpene hydrocarbon(s) and a polyoxyethylene-polypropylene block copolymer, the ratio of acrylic acid polymer to metabolizable oil/polyoxyethylene-polypropylene block copolymer mixture is typically in a 5 ratio of between about 1:25 and about 1:50. A metabolizable oil, a polyoxyethylene polypropylene block copolymer, and an acrylic acid polymer may be employed in the form of an oil in water emulsion wherein acrylic acid polymers are typically employed at a concentration of between about 0.5 g/Il and about 10 g/l; metabolizable oils are typically employed at a concentration of between about 2 mill and about 6 mi/l; and polyoxyethylene 10 propylene block copolymers are typically employed at a concentration of between about 1 ml/l and about 3 ml/I. Exemplary suitable adjuvant mixtures include, but are not limited to, mixtures of one or more acrylic acid polymer(s) with a mixture of metabolizable oil, for example an unsaturated terpene hydrocarbon or a hydrogenation product thereof, preferably squalane 15 (2,3,10,15,19,23-hexamethyltetracosane) or squalene, and a polyoxyethylene polyoxypropylene block copolymer. Such an acrylic acid polymer may be a homopolymer or a copolymer. Acrylic acid polymers are typically carbomers. Carbomers are commercially available under the trade name Carbopol and are described, for example, in U.S. Patent Nos. 20 2,909,462 and 3,790,665, each of which is incorporated herein by reference. The polyoxyethylene-polyoxypropylene block copolymers are surfactants, typically liquid surfactants, which aid in suspending solid and liquid components. Surfactants are commercially available as polymers under the trade name Pluronic@. The surfactant poloxamer 401 is commercially available under the trade name Pluronic@ L121. 25 The adjuvant mixture may comprise a metabolizable oil, an acrylic acid polymer and a polyoxyethylene-polyoxypropylene block copolymer formulated as an emulsion in an aqueous medium. Within certain embodiments, the adjuvant mixture may include a metabolizable oil and polyoxyethylene-polyoxypropylene block copolymer such as a mixture of squalane and Pluronic@ L121 (poloxamer 401) which may be present in an amount of 30 between about 50 ml/l and about 100 ml/I and the carboxymethylene polymer may be Carbopol 934P (Carbamer 934P), which may be present in amount of about 2 mi/l. Preferred acrylic acid polymers are those marketed by B. F Goodrich as Carbopol 934 P NF and 941 NF, which are polymers of acrylic acid cross-linked with polyallylsucrose and which have the chemical formula (CH 2 CHOOOH),. These polymers form aqueous gels 35 which suitably formulate with aqueous carriers. Polyoxyethylene-polypropylene block -19copolymers may be the nonionic surfactants marketed by BASF as Pluronic@ L121, L61, L81 or L101. Within certain embodiments, compositions disclosed herein may employ, in further combination, one or more other live bacteria, bacterin, toxoid, and/or viral antigen. Thus, 5 within certain aspects of these embodiments, the adjuvanted live avirulent M. hyopneumoniae composition may comprise an immunizing amount of a live virulent Mycoplasma hyopneumoniae and one or more biologically acceptable adjuvant in further combination with (a) one or more live bacteria such as, for example, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella 10 bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae, and leptospira bacteria; (b) one or more bacterin; (c) one or more purified toxoid from one or more pathogens such as, for example, Haemophilus parasuis, Pasteurefla multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae, and leptospira bacteria; and/or (d) one or more 15 viral antigen wherein the virus is selected from the group consisting of swine influenza virus (SIV; such as SIV strains H1NI, H1N2, and H3N2), porcine reproductive and respiratory syndrome virus (PRRSV), raccoon poxvirus expressing PRRS and/or other antigens, TGEV expressing PRRS and/or other antigens, and porcine circovirus (PCV). Exemplified herein are compositions, including vaccine compositions, which employ one or more live avirulent 20 Mycoplasma hyopneumoniae strain in further combination with porcine circovirus Type 1 Type 2 chimera modified live vaccine (cPCV1-2) (See U.S. Patent Publications 2003/0170270 and 2004/0253270). Within these or alternative embodiments, compositions, including vaccine compositions, may additionally or optionally include a preservative such as, for example, 25 thimerosol and/or EDTA. See, also, U.S. Patent Publication Nos. 200210131980 and 2003/0017171, each of which is herein incorporated by reference in its entirety. The concentration of such other live bacteria, bacterin, toxoid, and/or viral antigen employed in the compositions described herein will depend upon the nature of the bacterin, toxoid, and/or viral antigen and are typically present in the compositions described herein at 30 a final concentration of between about 0.5 x 105 to 0.5 x 10 " per ml. Alternatiively, the bacteria are present in a final concentration of between about 0.5 x 106 to 0.5 x 10 9 per ml or between about 0.5 x 10 7 to 0.5 x 100 per ml. Compositions of the present disclosure will find utility in methods for protecting an animal against disease caused by Mycoplasma hyopneumoniae and/or for preventing or 35 ameliorating an outbreak of such disease among animal populations by administration an -20- H:\amt\Intrwovn\NRPortbl\DCC\AMT\9243239_I.docx-5/01/2016 adjuvanted live avirulent Mycoplasma hyopneumoniae composition as described herein. Compositions described herein may also be advantageously employed in methods for enhancing in an animal an immune response, such as a cell-mediated and/or humoral immune response, to Mycoplasma hyopneumoniae. Such methods comprise the steps of 5 administering to an animal, typically swine, in one or two doses, a composition comprising one or more adjuvanted live avirulent Mycoplasma hyopneumoniae strain. Depending upon the precise application contemplated, compositions may be administered intramuscularly, subcutaneously, orally, by aerosol, or intranasally. According to the methods of the present disclosure, a desirable dosage regimen 10 involves administration of one or more doses of desired vaccine composition to the pig. Typically, where two doses are administered to the animal, the doses are administered between about one (1) week apart and about four (4) weeks apart, more typically between about two (2) weeks apart and about three (3) weeks apart. 15 EXAMPLES The present disclosure will be better understood by reference to the following non limiting examples: EXAMPLE 1: Preparation of an M. hyopneumoniae Avirulent Adjuvanted Live 20 Vaccine This Example discloses the preparation of an exemplary adjuvanted live avirulent M. hyopneumoniae composition according to the present disclosure. Mycoplasma hyopneumoniae may be obtained from any number of readily available sources. In one embodiment described herein, M. hyopneumoniae avirulent live 25 culture strain J (FCX3-Line 1), was obtained from the American Type Culture Collection (ATCC; Manassas, VA) as ATCC Strain No. 27715. Any other avirulent strain of M. hyopneumoniae may be used for preparation of the compositions, such as, for example, the parent J strain designated as ATCC accession number 25934. In certain other embodiments, it is envisioned that any live virulent strain of Mycoplasma pneumoniae, 30 may be modulated, attenuated or mutated until the culture is established to be avirulent, as determined by in vitro or in vivo testing, using procedures known to those skilled in the art. The full genomic sequence of the ATCC 25934 J strain has been published by Vasconcelos -21- H:\amt\Introvn\NRPortbl\DCC\AMT\9243239_I.docx-5/01/2016 et al (J. Bacterid. (2005), 187(16): 5568-5577) and has been assigned GenBank accession number AE017243 (SEQ ID NO:1). Several of the sequences associated with ATCC strain 25934 may be found in PubMed and have GenBank accession numbers AY737012 (16S ribosomal RNA gene), 5 -21A- AY512905 (adhesin gene, AF013714 (prolipoprotein p65 gene), U02538 (23S rRNA gene) and U02537 multidrug resistance protein homolog genes). Each vaccine composition for the bactericidal assay was prepared from one lyophilized vial of a M. hyopneumoniae culture rehydrated with 20 mi of normal saline. 5 Vaccine compositions included a combination of 5 ml of the rehydrated culture and adjuvant sufficient to acquire the specified adjuvant concentration in a final volume of 10 ml. A control composition was also prepared by combining 5 ml of rehydrated culture with 5 ml of normal saline. All compositions were mixed for 5 minutes prior to sampling. Samples were taken from all compositions at 5 minutes (0 hour), 3 hours, and 7 hours after blending. The 10 viability of each vaccine was determined by Colony Forming Units (CFU) at each sampling point (see Table 1). TABLE 1 CFU/mI MPN/ml Adjuvant 0 hour 3 hour 7 hour 0 hour 3 hour 7 hour 30% SL-CD 1.44E+07 0 0 1.15E+07 0 0 10%SL-CD 1.48E+07 6.40E+05 5.2E+03 2.87E+07 8.42E+050.OOE+00 Control 8.30E+07 1.06E+08 9.OE+07 3.62E+07 6.22E+07 3.62E+07 5% SP-Oil 9.46E+07 7.60E+07 2.55E+07 4.67E+07 9.40E+07 6.22E+06 5% SP-Oil /0.2% 1.50E+08 5.61 E+07 4.53E+07 4.27E+08 7.74 E+07 2.84E+06 Control 2.17E+08 1.41 E+08 9.86E+07 1.91 E+08 8.42E+07 4.67E+07 10%SP oil 1.09E+07 1.07E+07 7.13E+06 3.40E+06 7.74E+063.62E+06 Control 3.50E+07 4.75E+07 7.20E+07 1.03E+07 8.42E+073.14E+07 10rSp-oil+0.2%carbopol 5.20E+07 1.30E+07 8.13E+065.50E+07 1.91E+072.26E+06 0.2%carbopol 6.80E+07 6.67E+07 6.60E+07 1.63E+08 1.38E+08 4.45E+07 control 2.90E+07 no test 5.54E+07 1.23E+08 No test 1.38E+07 The average viability of the stock culture was determined by averaging all the control 15 viabilities at 0 hour, average 9.09 x 107 CFU/ml. In comparison, the most-probable number (MPN) was determined for the stock cultures resulting in 1.85 x 10" MPN/ml. Vaccine blending and vaccination typically takes less than 3 hours; therefore when looking at the bactericidal effect of adjuvants, the 3 hour time point is the most important. The trend for SP-Oil at 5% and 10% at the 3-hour sampling compared to the control is a 2-fold difference 20 and 4-fold difference, respectively. Vaccine A was prepared by rehydrating vials of lyophilized culture with diluent containing 10% (v/v) SP-Oil final concentration. The placebo vaccine was sterile normal saline. - 22 - EXAMPLE 2: In vivo Efficacy of M. hyopneumoniae Avirulent Adjuvanted Live Vaccines In Pigs This Example demonstrates the in vivo efficacy of exemplary adjuvanted live avirulent 5 M. hyopneumoniae vaccine compositions. A total of 30, four to six week-old pigs were acquired from Fort Dodge Animal Health's SPF herd in Charles City, Iowa. Pigs were maintained on feed without antibiotics or growth promotants and given water and food ad libitum. Animals receiving vaccine compositions and control compositions were housed in different rooms and all pigs were maintained under 10 similar conditions during vaccination, monitoring, and challenge periods. The 30 pigs were randomly assigned into three (3) groups as follows: One (1) group received a vaccine composition, one (1) group received a placebo, and one (1) group served as an environmental control. Pigs were grouped as shown in Table 2. 15 TABLE 2 Group Total# of Vaccine # Pigs pigs challenged 1 13 A 13 2 12 placebo 12 3 5 N/A N/A Four to six week-old pigs were vaccinated intramuscularly with a 2 ml dose of the appropriate vaccine. Group 1 was administered vaccine A, group 2 was administered the placebo. Pigs from group 3 were not vaccinated or challenged and served as environmental 20 controls. Pigs in group I were vaccinated twice, two weeks apart. Two weeks after the second vaccination, all pigs in groups I and 2 were challenged with a lung homogenate (LI 34) containing a virulent strain of M. hyopneumoniae Strain 11 (J. Clin. Microbiol.,1999 Mar;37(3):620-7) Four weeks after challenge, all pigs in groups 1-3 were necropsied and lung lesions were evaluated. 25 Preparation of Lunq Homogenate (LI-34) FOR M. hyopneumoniae Challenge Strain Seven cross-bred pigs were procured from Spring Prairie Colony Farms (Genetipork) and were inoculated intratracheally with 10 ml of a 1:30 dilution of a 10% crude lung homogenate (L131) of M. hyopneumoniae strain 11. The L131 crude lung homogenate had 30 been produced by passaging lung homogenate containing M. hyopneumoniae in specific -23pathogen free pigs and harvesting the resulting pneumonic lungs at early mid-stage of the disease. The lung homogenates were stored at -70* C until needed. Serum was collected upon arrival and at necropsy from all pigs and was evaluated at the ISU Veterinary Diagnostic Laboratory (ISU-VDL) for evidence of antibodies to TGE 5 (PRCV), SW and PRV. In addition, ELISA's for PRRSV and M. hyopneumaniae antibodies were performed and all samples were negative for all of the above respiratory pathogens. All pigs were necropsied. Pentobarbital was used to induce deep anesthesia of pigs prior to exsanguination. The ventral chest wall was opened and areas of pneumonic lesions typical of M. hyopneumoniae were removed aseptically and placed individually in sterile 10 containers. A small portion of each lung was ground and checked for purity on blood agar plates, beef heart infusion broth, and Friis media. Tube dilutions were performed in Friis media to titrate out the M. hyopneumoniae. Tie remaining lung pieces were frozen in 50 ml centrifuge tubes at -70* C until the results of the bacteriology and mycoplasma isolation were known. 15 Lung lobes from 3 of the 7 pigs were used to produce the M. hyopneumoniae lung inoculum. Lobe chunks were thawed from pigs #329, 331, and 332 and ground in Friis media containing no antibiotics. Purity of lung inoculum was confirmed by culture on beef heart infusion, blood agar and Friis media. Only micrococci consistent with environmental contamination were found on one plate. The lung inoculum was titrated for M. 20 hyopneumoniae levels and found to contain approximately 10 CCU/mI. An aliquot was submitted to ISU-VDL for virus isolation assays for SN, EMS, enterovirus, HEV, PRCV, PRRSV, Pseudorabies, TGE, parvovirus, and rotavirus. The results of all assays were negative. Final volume of ground lung inoculum (labeled LI 34) was 1780 ml from 178.1 grams of lung tissue. This was aliquoted into 100 X 5 ml and 110 X 10 ml volumes. 25 In the second phase of the study, 9 pigs were used in the determination of the concentration of lung inoculum required to induce an average of 8% pneumonic-lung lesions in a minimum of 80% of the pigs. All pigs were challenged with the L134 M. hyopneumoniae strain 11 intralracheally on as previously described. Challenge dilutions included 1:30, 1: 100, and 1:500. 30 The pigs were necropsied. Pentobarbital was used to induce deep anesthesia prior to exsanguination. The lungs were removed and lung lesions sketched on standard lung diaphrams. Serum was collected from all pigs and was assayed by ELISA for antibodies to M. hyopneumoniae. All pigs were either low positive or seronegative for M. hyopneumoniae suggesting no previous exposure to M. hyopneumoniae prior to arrival. Tracheal swabs were 35 collected aseptically from all pigs. Pasteurella multocida and Haemophilus parasuis were -24 isolated from 4 and 3 pigs respectively. M. hyopneumoniae was isolated from all challenged pigs. Lung sketches were evaluated with a Zeiss Image analysis system to determine the percentage of pneumonic lung lesions. 5 Conclusions The challenge of the pigs was successful and a dilution of 1:100 would be the optimal dilution to use. The average percentage of pneumonia induced was 10.17 +/- 6.6, which is higher than normal, however this may be attributed to the presence of Pasteurela multocide and/or parasvis in the pigs. In addition, 100% of the pigs inoculated with the challenge 10 inoculum had significant lung lesions. Overall, these results are fairly typical of what we observe in our studies of M. hyopneumoniae, in that if there are other pathogens present, there is an increase in pneumonia. This may be due to the interaction between the pathogens and the immune system. We produced 1,600 ml of M. hyopneumoniae lung inoculum for use in experimental challenge experiments. The inoculum will produce at least 15 8% or higher pneumonic lung lesions in a minimum of 80% of inoculated pigs when used at a 1: 100 dilution intratracheally. The vaccine was titrated prior to the day of vaccination and bactericidal assays were conducted to determine the appropriate adjuvant systems to be used (see Example 1). From these data, 10% SP-Oil adjuvant system was chosen for further study. The average 20 viability per vial of stock culture was 3.64 x 109 CFU/Bottle. On the day of the first administration, vaccine compositions were prepared as follows: Vaccine A - each of three vials of avirulent M. hyopneumoniae lyophilized culture was rehydrated with 10 ml of 10% SP-Oil diluent. The three vials of vaccine composition for each diluent type were pooled and allowed to mix for 20 minutes on a stir plate with stir bar. The 25 placebo was normal saline aliquoted into a sterile bottle for administration. The compositions remained on ice during the course of vaccination for 2 hours. On the day of the second administration, vaccine compositions were prepared as follows: Vaccine A -- each of three vials of avirulent M. hyopneumoniae lyophilized culture was rehydrated with 10 ml of 10% SP-Oil Diluent. The three vials of rehydrated culture for 30 each diluent type were pooled and allowed to mix for 20 minutes on a stir plate with stir bar. The placebo was normal saline aliquoted into a sterile bottle for administration. The compositions remained on ice during the course of vaccination for 2 hours. The concentration of viable M. hyopneumoniae in each composition was determined before and after administration. Viability was evaluated by determining Colony Forming 35 Units (CFU/ml). A vial of lyophilized stock culture was rehydrated with 10 ml of normal saline, - 25 allowed to mix for 20 minutes, and served as a control for the viability assay. Since the first control viability was lower than the test vaccine viability, during the second administration, two vials were rehydrated and pooled to serve as the control (see Table 3 for test vaccine viabilities and control viabilities). 5 TABLE3 First Vaccination Second Vaccination Vaccine CFU/mL CFU/mL Group 1: Adjuvant 10% SP-Oil 2.79E+08 2.27E+08 Viability Control 1.29E+08 2.69E+08 All pigs were observed daily for temperatures and clinical symptoms starting two days prior to each administration and continued for seven days after each administration. Pigs were observed for clinical symptoms, which included, but were not limited to, coughing, sneezing, nasal discharge, depression, inappetance, and labored breathing. 10 Fourteen days after the second administration, pigs in group 1 were challenged trans tracheally with a virulent strain of M. hyopneumoniae. On the day of challenge, a virulent M. hyopneumoniae challenge stock of frozen ( 70"C) lung homogenate (LI-34), was thawed rapidly under warm water and diluted (1:100 dilution) with. Pigs were sedated with a mixture of Xylazine-Ketamine-Telazol TM consisting 15 of 50 mg/ml Xylazine, 50 mg/ml Ketamine, and 100 mg/ml Telazol. Each pig was given 10 ml of the challenge material trans-tracheally. To ensure needle placement, air was drawn into the syringe prior to administration of the challenge material. All pigs were observed daily for clinical symptoms post-challenge. Pigs were bled for serum on days 0, 14, 28, and 56. Serological response of the pigs 20 to M. hyopneumoniae challenge was determined by ELISA. Four weeks after challenge, all pigs from groups 1-3 were euthanized and lungs were removed. Test groups were blinded and scored for gross lung lesions. Atypical M. hyopneumoniae lesions were formalin fixed for subsequent histopathological evaluation. Swab samples from affected lung were collected for bacterial isolation. 25 The average lung lesion score for pigs in group 1 (5.9%) was approximately 50% less than the placebo group (14.8%). When the statistical analysis was adjusted for litter, the mitigated fraction for group 1 was 69.2% reduction in severity of lung lesions when compared to controls. These data are summarized in Table 4. All of the pigs were sero negative on the day of first administration indicating that the pigs were susceptible to M. 30 hyopneumoniae infection. With the exception of one (1) pig in the SP-Oil group, pigs did not - 26 sero-convert after the first vaccination. All pigs receiving the SP-Oil adjuvanted vaccine composition developed an antibody response after the second shot. Serological response demonstrates that an immune response to M. hyopneumoniae was elicited. (See Table 9. for serology results) 5 TABLE4 Vaccine Description Mitigated Fraction Mitigated Fraction Reduction in Lesions Reduction Lower Compared to Control Confidence Level Vaccine A Avirulent M. 69.2 40.2 hyopneumoniae live with 10% SP-Oil Control Placebo NA NA The statistical analysis of the data must meet the criteria for the mitigated fraction (<50% with lower confidence level >30%) for reduction in lung lesions for a vaccine to be considered efficacious for M. hyopneumoniae. In total, these data demonstrate that a live 10 avirulent adjuvanted M. hyopneumoniae may be advantageously employed for eliciting a protective immune response when administered in vivo to an animal. While the invention has been described in each of its various embodiments, it is expected that certain modifications thereto may be undertaken and effected by the person skilled in the art without departing from the true spirit and scope of the Invention, as set forth 15 in the previous description and as further embodied in the following claims. The present disclosure is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the 20 appended claims. It is further to be understood that all values are approximate, and are provided for description. All patents and patent applications cited herein are hereby incorporated herein by reference in their entireties. EXAMPLE 3: Preliminary ImmunogenIcity Study of the Mycoplasma hyopneumoniae 25 Fraction of Mycoplasma hyopneumoniae Live Avirulent strain-Porcine Circovirus Type 1-Type 2 Chimera Modified Live Combination Vaccine in 3-4 Week Old Pigs This Example discloses the efficacy of a combination vaccine comprising an adjuvanted live avirulent Mycoplasma hyopneumoniae J (FCX3-linel) strain and a Porcine - 27 - Circovirus (PCV) Type 1-Type 2 Chimera live vaccine (cPCVI-2; see U.S. Patent Nos. 7,279,166 and 7,276,353) when administered intramuscularly (IM) or intranasally (IN) in 3-4 week old pigs. This combination vaccine (PCV/MH) is suitable for use for the vaccination of healthy swine as an aid in the prevention and/or to reduce the severity of disease caused by 5 M. hyopneumoniae and Porcine Circovirus. The targeted test vaccine should contain about 4.0 Log 10

FAID

50 /dose of cPCV1-2 modified live virus and 4x10" CFU/dose of M. hyopneumoniae J strain (see King et at, Journal of Comparative Medicine and Vet. Science, 29: 85-89 (1965) and U.S. patent number 4,824,785 for the FAID method). The vaccine was adjuvanted to contain 10% (v/v) 10 S P-OC1 final concentration. The placebo vaccine was sterile Normal Saline. A total of 66 3-4 week-old pigs were employed in this study. 16 pigs were administered 2 ml of PCV/MH live vaccine intramuscularly once and challenged (Group 1); 15 pigs were administered 2 ml of PCV/MH live vaccine intramuscularly twice (two weeks apart) and challenged (Group 2): 15 pigs were administered 2 ml (1 ml/nostrii) of PCV/MH 15 live vaccine intranasally twice (two weeks apart) and challenged (Group 3); 15 pigs were not administered the PCV/MH live vaccine and challenged (Group 4); and 5 pigs served as environmental controls (Group 5). The vaccine used in the study disclosed herein was a combination of MH lyophilized live antigen (lot#1744-56) and diluent containing PCV (LotC108-56) live vaccine. On the day 20 of vaccination, the lyophilized live MH cake was rehydrated with diluent containing PCV live virus (4.0Log 1 0 FAIDqo/mL adjuvanted with 10% SP Oil). Final vaccine was assigned Lot# 2315-30. Viability for the MH fraction was determined before and after vaccination, 3.18 x 108 CFU/mL (before) and 1.65 x 10 8 CFU/mL (after), respectively. The PCV titer for the vaccine pre and post vaccination was 4.09 Log 1 o FAID 60 and 3.7 Logo FAID.o, respectively. 25 The vaccine for second vaccination was prepared as above and assigned Lot# 2315-32. Viability for the MH fraction was 1.24 x 108 CFU/mL and 1.5x 106 CFU/mL pre and post vaccination respectively. The viability for the PCV fraction was 4.36 Logo FAID5o and 3.83 Log 10 FAID5o, respectively. The pigs were observed for 7 days following vaccination for any adverse reactions to 30 the vaccine. Three pigs died during the post vaccination observation period due to non-MH or PCV related causes. A summary of the clinical observations from the post vaccination period is found in Table 5. - 28 - Table 5 Group # of Treatment Route Dosage Observation after vaccination pigs 1 16 Vaccination IM 1 dose One pig was noted to have elevated temp (105.1-106.2 0 F) for 7 consecutive days starting on fifteen days post first vaccination. Another pig was noted to have an elevated temp, inappetance and depression for 4 consecutive days starting 18 days post first vaccination. 2 15 Vaccination IM 2 doses One pig died the day before second vaccination due to possible HPS or S. suis infection. Clinical signs of depression and thin were noted prior to vaccination. One pig had 3 consecutive days of elevated temp (105.0-106.7"F) starting 5 days post first vaccination. 3 15 Vaccination IN 2 doses Two days prior to second vaccination one pig died due to intestinal perforation. Two pigs had swollen joints and coughing for 8 consecutive days, which had originated prior to first vaccination. Two other pigs one day prior to second vaccination was noted to have swollen hocks for 7 consecutive days in which one resulted in an abscess, the other healed. 4 15 Saline IM 2doses One pig was noted to have swollen hocks throughout the study noted prior to first vaccination. Another pig also had swollen hocks for - 29 several days during the study. One pig had two days of elevated temp. for two consecutive days 105.1"F and 106.5 0 F starting 6 days after second vaccination. 6 5 No NA NA Housed with group 4 pigs during Vaccination vaccination. No adverse reactions noted. NA: Not applicable IN: intranasal IM: intramuscular All pigs in Groups 1-4 were challenged with a virulent strain of M. hyopneumoniae (pig 5 lung homogenate containing virulent MH (LI-34)). Pigs from Group 1 were challenged four weeks after first vaccination. Pigs in Groups 2-4 were challenged two weeks after second vaccination. At four weeks after challenge, all pigs in Groups 1-5 were necropsied and lung lesions were evaluated. The vaccine was titrated prior to the day of vacccination. Lyophllized culture of 10 avirulent M. hyopneumoniae was rehydrated on the day of vaccination. The concentration of M. hyopneumoniae organisms in the vaccine was approximately 2 x 108 CFU/mI. A sample of vaccine was retained and a viability assay performed before and after vaccination to confirm actual CFU/ml. The vaccine was held on ice during the course of vaccination. All pigs were observed daily for temperatures and clinical signs starting two days prior 15 to each vaccination continuing for seven days after each vaccination. Pigs were observed for clinical symptoms, which included, but were not limited to, coughing, sneezing, nasal discharge, depression, inappetance, and labored breathing. 14 days after the second vaccination, pigs in Groups 1-4 were challenged trans-tracheally with a virulent strain of M. hyopneumoniae. 20 On the day of challenge, the virulent M. hyopneumoniae challenge stock, a frozen ( 70*C) lung homogenate (LI-34) was thawed rapidly under warm water and diluted (1:100 dilution) using sterile M. hyopneumoniae growth medium. Pigs were sedated with a mixture of Xylazine-Ketamine-Telazol TM comprising 50 mg/ml Xylazine, 50 mg/ml Ketamine and 100 mg/mi Telazol. Each pig was given 10 ml of the challenge material transtracheally. To 25 ensure needle placement, air was drawn into the syringe prior to administration of the challenge material. - 30 - All pigs were observed grossly for clinical signs after challenge. The observation was conducted daily for any abnormal clinical sign. Pigs were bled for serum (no more than 13 ml whole blood) on day 0, 14, 28, and 66 of the study. Serum was collected, but not evaluated. ELISA may be conducted to evaluate serological response of the pigs using the 5 serum collected during the study period in the future. Four weeks after challenge, all pigs from Groups 1-5 were euthanized and lungs were removed. Atypical M. hyopneumoniae lesions were formalin fixed and the samples were examined for histopathology. Swab samples from affected lung were collected for bacterial isolation. Pigs that died after challenge were necropsied and samples collected as 10 described above. Vaccine efficacy was defined as a combined average lung lesion score of the vaccinates that was 50% less than the combined average lung lesion score of the controls. On the day of necropsy all pigs were euthanized, lung lesions scored and swabbed for bacterial isolation. Bacteria isolated from the swabs consisted of the following: 15 Staphylococcus heamolyticus, Streptococcus suis (P322), Staphylococcus epidermis, A. pyogenes, aerococus species, S. uberis, Bordetella bronchiseptica (P344) and Microbacterium. The statistical analysis for the Lung lesion scores is in Table 6. Table 6 Group Protection MF litter MF Lower Litter LCL lung Standard Mean ratio adjusted confidence adjusted lesion deviation percentile level percent score of lung for lesions lung lesion lesion score Vaccinate IM single dose 1/15 52.9% 19.6% 6.30% 3.86% 4.41 0.37 Vaccinate IM double dose 3/15 63.8% 33,8% 5.03% 2.39% 4.59 0.31 Vaccinate IN double dose 0/14 -8.6% -51.8% 12.86% 8.59% 7.38 0.65 Control 0/15 NA NA 11.46% 8.41% 5.5 0.62 20 LCL= Lower Confidence Level MF=Mitigated Fraction - 31 - The statistical analysis of the data met the criteria for the mitigated fraction (<50%, with LCL >30%) for reduction in lung lesions. This example demonstrates (a) the efficacy of the MH/PCV vaccine for the MH fraction with two 2 mL doses administered IM, at 3.18 x 108 CFU/mL and (b) the safety of the MH/PCV vaccine due to lack of clinical signs related to MH 5 or PCV following vaccination. EXAMPLE 4: Immunogenicity Study of the Mycoplasma hyopneumoniae Fraction of Mycoplasma hyopneumoniae Live Avirulent strain- Porcine Circovirus Type 1-Type 2 Chimera Modified Live Combination Vaccine in 3-4 Week Old Pigs 10 This Example discloses an immunogenicity study which supports the results from the study presented in Example 4 and confirms the efficacy of the M hyopneumoniae fraction of Mycoplasma hyopneumoniae live avirulent strain-Porcine Circovirus Type 1-Type 2 (cPCVI 2) chimera modified live vaccine combined vaccine (MH/PCV) when administered intramuscularly. The MH/PCV vaccine disclosed herein may be suitably employed for the 15 vaccination of healthy swine as an aid in preventing and/or minimizing the severity of disease caused by M, hyopneumoniae and Porcine Circovirus. The pigs used in the present study were sero-negative to M. hyopneumoniae as determined by ELISA. A total of 79, three to four week-old pigs were randomized into four groups. 24 pigs, 20 Group 1, were vaccinated with a single dose of the combination PCV/MH live vaccine. 24 pigs, Group 2, were vaccinated with the combination vaccine twice two weeks apart. 24 pigs, Group 3, were vaccinated with normal saline twice two weeks apart to serve as challenge controls. All vaccines were administered intramuscularly. Four pigs, Group 4, were neither vaccinated nor challenged and served as environmental controls. 25 The vaccine used in the study was a combination of MH lyophilized live antigen (Lot1744-66) and diluent containing PCV (cPCV1-2 LotC108-56) live vaccine. On the day of vaccination, the lyophilized live MH cake was rehydrated with diluent containing PCV live virus (3.5LogjoFAIDoo/mL adjuvanted with 10% SP Oil ). Final vaccine was given Lot2315 40. Viability for the MH fraction was determined before and after vaccination, 2.09 x 108 30 CFU/mL and 1.56 x 108 CFUlmL respectively. The placebo vaccine was sterile normal saline. The vaccine for second vaccination was prepared as above and given Lot# 2315-42. Viability for the MH fraction was 1.05 x 108 CFU/mL and 6.72x 107 CFU/mL pre and post vaccination respectively. The viability for the PCV fraction diluent was 3.44 Log 1 o FAID 50 . - 32 - The vaccine was titrated prior to the day of vacccination. Lyophilized culture of avirulent M. hyopneumoniae was rehydrated on the day of vaccination. A sample of vaccine was retained and a viability assay performed before and after vaccination to determine CFU/ml. The vaccine remained on ice during the course of vaccination. 5 All pigs were observed daily for temperatures and clinical signs starting two days prior to each vaccination continuing for 7 days after each vaccination. Pigs were observed for clinical symptoms, which included, but were not limited to, coughing, sneezing, nasal discharge, depression, inappetance, and labored breathing. The pigs were observed for 7 days following vaccination for any adverse reactions to 10 the vaccine. Three pigs died during the post vaccination observation period due to non-MH or PCV related causes. A summary of the clinical observations from the post vaccination period is found in Table 7. Table 7 Group # of pigs Treatment Dosage Observation after vaccination 1 24 Vaccination 1 dose No adverse reactions noted due to vaccination 2 24 Vaccination 2 One pig died in this group due to doses intestinal perforation. On 5 days post first vaccination one pig had a temp of 105.5*F and labor breathing noted for one day. 3 24 Saline NA On 6 days post first vaccination one pig vaccination was noted with labor breathing for a single day. 4 4 No NA Housed with group 3 pigs during Vaccination vaccination. No adverse reactions noted. NA: Not applicable 15 Ali pigs in Groups 1-3 were challenged with a virulent strain of M. hyopneumoniae at approximately 7 weeks of age. Pigs from Group I were challenged four weeks after first vaccination. Pigs in Groups 2 and 3 were challenged two weeks after second vaccination. The virulent M. hyopneumoniae challenge stock, a frozen (-70*C) lung homogenate (LI-34) was thawed rapidly under warm water and diluted (1:100 dilution) using sterile M. 20 hyopneumoniae growth medium. Pigs were sedated with a mixture of Xylazine-Ketamine TelazoITM comprising 50 mg/ml Xylazine, 50 mg/ml Ketamine, and 100 mg/ml Telazol. Each pig was given 10 ml of the challenge material trans-tracheally. Pigs were bled for serum on day 0, 14, 28, and 56 of the study. Serum samples collected from this study may be tested to evaluate animal serological response to M. 25 hyopneumoniae and PCV2 using ELISA methods well known in the art. Serum samples - 33 collected from zero-days post vaccination (ODPV) and zero-days post challenge (ODPC) may be tested for antibodies to M. hyopneumoniae, Swine influenza (H1N1), and porcine reproductive and respiratory syndrome (PRRS) using commercially available ELISA test kits. Four weeks (28 DPC) after challenge, all pigs from groups 1-4 were euthanized and 5 lungs were removed. Lung lesion scores were recorded and typical M. hyopneumoniae lesions were formalin fixed. Samples were examined for histopathology. Swab samples from one M. hyapneumoniae affected lobe were collected for bacterial isolation for detection of secondary infections. In addition, bronchial alveolar lavage fluid was collected. The lungs were lavaged with phosphate buffered saline and the resulting fluid was aliquoted for testing 10 by PCR. For the evaluation of reduction in the severity of lung lesions, the estimator was the mitigated fraction (MF) statistic. The mitigated fraction was calculated as: MF- 2W - n(l+ n, +n,) where: 15 W1 = Wilcoxon Rank sum statistic nc = number of subjects in the control group nv = number of subjects in the vaccinated group The 95% confidence interval for the mitigated fraction was calculated. For the claim of reduction in severity of lung lesions: 20 Ho:MV=Mc HA: Mv Mc where: Mv = Median of the lung lesion score in the vaccinated group Mc = Median of the lung lesion score in the control group 25 The frequency distribution of the continuous outcome variables was assessed using PROC UNIVARIATE, which performs parametric and nonparametric analysis of a sample from a single population. (SAS Institute Inc., Cary NC). Log transformations of the antibody titers were employed to meet the normality assumption required for parametric tests. Baseline evaluations to evaluate comparability of groups for litter and room will be made by 30 chi-square. The severity of lung lesions was compared between each vaccinated group and the control group by Wilcoxon rank sum test (PROC NPAR1WAY with lung lesion score as the dependent variable and treatment included as an independent variable. PROC -34- NPAR1 WAY, which performs nonparametric tests for location and scale differences across a one-way classification; PROC NPARIWAY also provides a standard analysis of variance on the raw data and statistics based on the empirical distribution function. (SAS Institute Inc., Cary NC). 5 All statistical analysis will be performed using the SAS system. In cases where transformation did not improve the distribution of the residuals for any transformed variables as determined by the W test for normality, non-parametric tests were employed as needed. The level of significance will be set at p<0.05. On the day of necropsy all pigs were euthanized, Jung lesions scored and swabbed for 10 bacterial isolation. Bronchoalveolar lavages (BAL) were also collected. Bacteria Isolated from the swabs consisted of the following: Actinobacillus species, Moraxella osloensis, Streptococcus sanguinis, A. pyogenes and Bordetella bronchiseptica. BAL samples were tested for MH by PCR methodology; two samples from environmental control group with lesions recorded and two samples with low lesion scores in the vaccinate and control group. 15 BAL samples for both pigs from the environmental control group with lesions were negative and both pigs in with low lesion scores in the vaccinate group were positive. The statistical analysis for the lung lesion scores is in Table 8. Table 8 Group Protection MF litter MF Lower Litter LCL lung Standard Mean ratio adjusted confidence adjusted lesion deviation of percentile level percent score lung lesion for lesions lung lesion score Vaccinate IM single dose 1/23 58.4% 31% 8.84% 6.68% 4.99 0.38 Vaccinate IM double dose 4/19 71.2% 48.7% 6.62% 4.37% 4.67 0.3 Control 0/23 NA NA 19.27% 14.62% 10.76 0.69 LCL= Lower Confidence Level 20 MF=Mitigated Fraction The statistical analysis of the data met the criteria for the mitigated fraction (<50%, with LCL >30%) for reduction in lung lesions. The vaccine is considered efficacious for the MH fraction with a 2mL dose administered FM, either single dose or double dose, at 2.09 x 25 108 CFU/mL. In addition the vaccine is considered safe due to lack of clinical signs related to MH or PCV following vaccination. - 35 - TABLE 9 SEROLOGY RESULTS FOR EXAMPLE 2 Pig ID Group ODPV1 0DPV2 ODPC Necropsy Lung score 730 1 <50 100 400 400 9.5 733 1 <50 <50 100 >400 35.5 735 1 <50 <50 100 200 5.5 740 1 <50 <50 200 400 5.5 742 1 <50 <50 200 200 0.5 745 1 <50 <50 200 100 0.9 754 1 <50 <50 400 400 6.8 755 1 <50 <50 400 >400 0.0 761 1 <50 <50 200 200 4.5 762 1 <50 <50 >400 200 0.5 763 1 <50 <50 400 200 2.7 771 1 <50 <50 >400 >400 5.5 774 1 <50 <50 >400 >400 0.0 732 2 <50 <50 <50 <50 1.8 738 2 <50 <50 <50 <50 5.9 739 2 <50 <50 <50 50 18.2 743 2 <50 <50 <50 50 19.1 747 2 <50 <50 <50 200 0.5 749 2 <50 <50 <50 50 21.4 752 2 <50 <50 <50 <50 9.5 759 2 <50 <50 <50 <50 15.9 764 2 <50 <50 <50 <50 26.4 768 2 <50 <50 <50 <50 31.8 769 2 <50 <60 <50 <50 16.8 773 2 <50 <50 <50 <50 10.0 726 3 <50 <50 <50 <50 0.0 744 3 <50 <50 <50 <50 0.0 750 3 <50 <50 <50 <50 0.0 3 <50 <50 <50 <50 1.4 770 3 <50 <50 <50 <50 0.5 Group 1: SP Oil vaccine (vaccinated and challenged) 5 Group 2: Control/challenge (unvaccinated and challenged) Group 3: Non-challenged control (unvaccinated and not challenged) ODPV1 and ODPV2: The numbers indicate the highest dilution that was positive in the ELISA test after the first dose of vaccine (ODPV1) or after the second dose of vaccine (ODPV2). - 36 - C:\NRPortb\DCC\RXSk48O5418_.DOC- IUl/12 -37 ODPC: The numbers indicate the ELISA results Post Challenge. The higher number indicates seroconversion. Lung Score: The number indicates the percent of lesions in the lungs of the animals. The higher number indicates a greater number of lung lesions due to a lack of protective immunity. The lower number indicates a healthier pig with fewer lesions due to induction of a protective immune response. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Claims (25)

1. A composition for eliciting an anti-Mycoplasma hyopneumoniae immune response in an animal, said composition comprising an immunologically effective amount of a live avirulent strain of Mycoplasma hyopneumoniae and the biologically acceptable adjuvant SP-Oil, wherein the live avirulent strain of Mycoplasma hyopneumoniae is a strain whose genome comprises a nucleic acid sequence having at least 95% homology to the nucleic acid sequence of SEQ ID NO: 1, which defines the nucleic acid sequence of the Mycoplasma hyopneumoniae J strain deposited under GenBank Accession Number AEO 17243.

2. The composition of claim 1, wherein the live avirulent strain of Mycoplasma hyopneumoniae is a J strain having ATCC Accession Number 25934 or an isolate thereof.

3. The composition of claim 1, wherein the live avirulent strain of Mycoplasma hyopneumoniae is a J strain designated as ATCC Accession Number 25934 or 27715.

4. The composition of claim 3, wherein the live avirulent strain of Mycoplasma hyopneumoniae is a J strain designated as ATCC Accession Number 27715.

5. The composition of any one of claims 1 to 4, wherein said SP-Oil is present at a concentration between about 1% and about 25%.

6. The composition of claim 5, wherein said SP-Oil is present at a concentration of about 10%.

7. The composition of any one of claims 1 to 6, further comprising one or more live bacteria, bacterins and/or one or more purified toxoids selected from the group consisting of Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella cholerasuis, Erysipelothrix rhusiopathlae, and leptospira bacteria. -38 - H:\amt\Intenovcn\NRPortbl\DCC\AMT\7896445_ L.docx-17/06/2015

8. The composition of any one of claims 1 to 7, further comprising one or more viral antigens selected from the group consisting of a swine influenza virus (SIV) antigen, a porcine reproductive and respiratory syndrome virus (PRRSV) antigen, raccoon poxvirus expressing PRRS, TGEV expressing PRRS, and a porcine circovirus (PCV) antigen.

9. The composition of claim 8, wherein said porcine circovirus (PCV) antigen is a Porcine Circovirus Type 1-Type 2 (cPCV1-2) chimera.

10. The composition of any one of claims 1 to 9, wherein the immune response elicited by a live-avirulent strain of Mycoplasma hyopneumoniae protects an animal against infection with, or reduces the severity of at least one symptom associated with an infection by a virulent strain of Mycoplasma hyopneumoniae.

11. The composition of claim 2, wherein the isolate of ATCC Accession Number 25934 is a strain having ATCC Accession Number 27715.

12. A method for protecting an animal against a disease associated with a virulent strain of Mycoplasma hyopneumoniase, or for preventing or reducing at least one symptom associated with the disease, said method comprising the step of administering to said animal the composition according to any one of claims 1 to 11.

13. The method of claim 12, wherein the step of administering is achieved by parenteral administration.

14. The method of claim 13, wherein the parenteral administration step is achieved by intramuscular injection.

15. The method of claim 12, wherein the step of administering is achieved by oral administration.

16. The method of claim 15, wherein the oral administration step is achieved by hand - 39 - H:\amt\lnterwo en\NRPortbl\DCC\AMT\7896445_.docm-17/06/2015 delivery or mass application.

17. The method of claim 12, wherein the step of administering is achieved by nasal administration.

18. The method of any one of claims 12 to 17, wherein said animal is a pig.

19. A method of preventing or ameliorating an outbreak of Mycoplasma hyopneumoniae, which comprises the step of administering to an animal the composition of any one of claims I to 11.

20. A method for enhancing an immune response to Mycoplasma hyopneumoniae, said method comprising the step of administering to an animal a single or multiple dose of the composition of any one of claims 1 to 11.

21. The method of claim 19 or claim 20, wherein the composition is administered to the animal in two doses.

22. The method of claim 21, wherein the second dose is administered two to three weeks after the first dose.

23. Use of the composition of any one of claims 1 to 11 in the manufacture of a medicament for protecting an animal against a disease associated with a virulent strain of Mycoplasma hyopneumoniase, or for preventing or reducing in an animal at least one symptom associated with the disease.

24. Use of the composition of any one of claims 1 to 11 in the manufacture of a medicament for preventing or ameliorating an outbreak of Mycoplasma hyopneumoniae in an animal.

25. Use of the composition of any one of claims 1 to 11 in the manufacture of a - 40 - H:amit\Lntcnvovcn\NRPortbl\DCC\AMT\7896445_ l.dox-17/06/2015 medicament for enhancing an immune response to Mycoplasma hyopneumoniae in an animal. -41- 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016 2012261741 05 Jan 2016